Molecular imaging targeting peptide receptors (Q37424334)

20 August 2017

1 reference

title

Molecular imaging targeting peptide receptors (English)

1 reference

20 August 2017

Margret Schottelius

1

1 reference

PubMed ID

19324088

20 August 2017

Hans-Jürgen Wester

series ordinal

2

1 reference

20 August 2017

24 March 2009

1 reference

20 August 2017

1 reference

20 August 2017

48

1 reference

20 August 2017

2

1 reference

20 August 2017

161-177

1 reference

Localisation of endocrine-related tumours with radioiodinated analogue of somatostatin

20 August 2017

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2009.03.012

Somatostatin receptor scintigraphy with [111In-DTPA-D-Phe1]- and [123I-Tyr3]-octreotide: the Rotterdam experience with more than 1000 patients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2009.03.012

Improvement of pharmacokinetics of radioiodinated Tyr(3)-octreotide by conjugation with carbohydrates

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2009.03.012

Comparison of radioiodinated TOC, TOCA and Mtr-TOCA: the effect of carbohydration on the pharmacokinetics

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2009.03.012

[123I]Mtr-TOCA, a radioiodinated and carbohydrated analogue of octreotide: scintigraphic comparison with [111In]octreotide

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2009.03.012

[111In-DTPA-D-Phe1]-octreotide, a potential radiopharmaceutical for imaging of somatostatin receptor-positive tumors: synthesis, radiolabeling and in vitro validation.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2009.03.012

Preclinical comparison in AR4-2J tumor-bearing mice of four radiolabeled 1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid-somatostatin analogs for tumor diagnosis and internal radiotherapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2009.03.012

DOTA-lanreotide: a novel somatostatin analog for tumor diagnosis and therapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2009.03.012

Somatostatin receptor-binding peptides labeled with technetium-99m: chemistry and initial biological studies

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2009.03.012

[99mTc]Demotate, a new 99mTc-based [Tyr3]octreotate analogue for the detection of somatostatin receptor-positive tumours: synthesis and preclinical results

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2009.03.012

99mTc-Demotate 1: first data in tumour patients-results of a pilot/phase I study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2009.03.012

99mTc-EDDA/HYNIC-TOC: a new 99mTc-labelled radiopharmaceutical for imaging somatostatin receptor-positive tumours: first clinical results and intra-patient comparison with 111In-labelled octreotide derivatives

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2009.03.012

99mTc-EDDA/HYNIC-octreotate scintigraphy, an efficient method for the detection and staging of carcinoid tumours: results of 3 years' experience.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2009.03.012

Detection of somatostatin receptor-positive tumours using the new 99mTc-tricine-HYNIC-D-Phe1-Tyr3-octreotide: first results in patients and comparison with 111In-DTPA-D-Phe1-octreotide

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2009.03.012

Pre-therapeutic dosimetry and biodistribution of 86Y-DOTA-Phe1-Tyr3-octreotide versus 111In-pentetreotide in patients with advanced neuroendocrine tumours

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2009.03.012

Neuroendocrine tumor targeting: study of novel gallium-labeled somatostatin radiopeptides in a rat pancreatic tumor model

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2009.03.012

Functional imaging of neuroendocrine tumors with combined PET/CT using 68Ga-DOTATATE (DOTA-DPhe1,Tyr3-octreotate) and 18F-FDG.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2009.03.012

Are radiogallium-labelled DOTA-conjugated somatostatin analogues superior to those labelled with other radiometals?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2009.03.012

DOTA-NOC, a high-affinity ligand of somatostatin receptor subtypes 2, 3 and 5 for labelling with various radiometals

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2009.03.012

PET imaging of somatostatin receptors: design, synthesis and preclinical evaluation of a novel 18F-labelled, carbohydrated analogue of octreotide.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2009.03.012

Modulation of pharmacokinetics of radioiodinated sugar-conjugated somatostatin analogues by variation of peptide net charge and carbohydration chemistry

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2009.03.012

Synthesis and evaluation of glycosylated octreotate analogues labeled with radioiodine and 211At via a tin precursor

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2009.03.012

Radioiodine and 211At-labeled guanidinomethyl halobenzoyl octreotate conjugates: potential peptide radiotherapeutics for somatostatin receptor-positive cancers

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2009.03.012

Influence of different spacers on the biological profile of a DOTA-somatostatin analogue.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2009.03.012

Radiolabeled somatostatin receptor antagonists are preferable to agonists for in vivo peptide receptor targeting of tumors

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2009.03.012

[(99m)Tc]Demotate 2 in the detection of sst(2)-positive tumours: a preclinical comparison with [(111)In]DOTA-tate

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2009.03.012

Preclinical evaluation of [99mTc/EDDA/tricine/HYNIC0, 1-Nal3, Thr8]-octreotide as a new analogue in the detection of somatostatin-receptor-positive tumors

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2009.03.012

New pansomatostatin ligands and their chelated versions: affinity profile, agonist activity, internalization, and tumor targeting

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2009.03.012

Preparation and biological evaluation of copper-64-labeled tyr3-octreotate using a cross-bridged macrocyclic chelator

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2009.03.012

Preparation and biological evaluation of 64Cu-CB-TE2A-sst2-ANT, a somatostatin antagonist for PET imaging of somatostatin receptor-positive tumors

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2009.03.012

First (18)F-labeled tracer suitable for routine clinical imaging of sst receptor-expressing tumors using positron emission tomography

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2009.03.012

Proof of principle for the use of 11C-labelled peptides in tumour diagnosis with PET.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2009.03.012

Imaging of metastatic melanoma utilising a technetium-99m labelled RGD-containing synthetic peptide.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2009.03.012

99mTc-NC100692--a tracer for imaging vitronectin receptors associated with angiogenesis: a preclinical investigation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2009.03.012

Imaging of integrin alphavbeta3 expression

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2009.03.012

Radiosynthesis and biodistribution of cyclic RGD peptides conjugated with novel [18F]fluorinated aldehyde-containing prosthetic groups

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2009.03.012

Phase I trial of the positron-emitting Arg-Gly-Asp (RGD) peptide radioligand 18F-AH111585 in breast cancer patients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2009.03.012

68Ga- and 111In-labelled DOTA-RGD peptides for imaging of alphavbeta3 integrin expression

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2009.03.012

Improved targeting of the alpha(v)beta (3) integrin by multimerisation of RGD peptides

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2009.03.012

Synthesis of DOTA-conjugated multivalent cyclic-RGD peptide dendrimers via 1,3-dipolar cycloaddition and their biological evaluation: implications for tumor targeting and tumor imaging purposes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2009.03.012

Preparation and characterization of 99mTc(CO)3-BPy-RGD complex as alphav beta3 integrin receptor-targeted imaging agent.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2009.03.012

Evaluation of a (99m)Tc-labeled cyclic RGD tetramer for noninvasive imaging integrin alpha(v)beta3-positive breast cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2009.03.012

In vivo imaging of tumour angiogenesis in mice with the alpha(v)beta (3) integrin-targeted tracer 99mTc-RAFT-RGD.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2009.03.012

(68)Ga-labeled multimeric RGD peptides for microPET imaging of integrin alpha(v)beta (3) expression

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2009.03.012

MicroPET imaging of breast cancer alphav-integrin expression with 64Cu-labeled dimeric RGD peptides

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2009.03.012

Integrin alpha v beta 3-targeted imaging of lung cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2009.03.012

(64)Cu-labeled tetrameric and octameric RGD peptides for small-animal PET of tumor alpha(v)beta(3) integrin expression

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2009.03.012

18F-labeled RGD peptide: initial evaluation for imaging brain tumor angiogenesis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2009.03.012

MicroPET imaging of brain tumor angiogenesis with 18F-labeled PEGylated RGD peptide

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2009.03.012

18F-labeled mini-PEG spacered RGD dimer (18F-FPRGD2): synthesis and microPET imaging of alphavbeta3 integrin expression.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2009.03.012

microPET of tumor integrin alphavbeta3 expression using 18F-labeled PEGylated tetrameric RGD peptide (18F-FPRGD4)

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2009.03.012

Click chemistry for (18)F-labeling of RGD peptides and microPET imaging of tumor integrin alphavbeta3 expression

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2009.03.012

Chemoselective pre-conjugate radiohalogenation of unprotected mono- and multimeric peptides via oxime formation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2009.03.012

Targeting of cholecystokinin-B/gastrin receptors in vivo: preclinical and initial clinical evaluation of the diagnostic and therapeutic potential of radiolabelled gastrin

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2009.03.012

Improved kinetic stability of DTPA- dGlu as compared with conventional monofunctional DTPA in chelating indium and yttrium: preclinical and initial clinical evaluation of radiometal labelled minigastrin derivatives

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2009.03.012

Improved tumour detection by gastrin receptor scintigraphy in patients with metastasised medullary thyroid carcinoma.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2009.03.012

Macrocyclic chelator-coupled gastrin-based radiopharmaceuticals for targeting of gastrin receptor-expressing tumours.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2009.03.012

Targeting of a CCK(2) receptor splice variant with (111)In-labelled cholecystokinin-8 (CCK8) and (111)In-labelled minigastrin

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2009.03.012

99mTc-labeling and in vitro and in vivo evaluation of HYNIC- and (Nalpha-His)acetic acid-modified [D-Glu1]-minigastrin.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2009.03.012

99mTc-labelled HYNIC-minigastrin with reduced kidney uptake for targeting of CCK-2 receptor-positive tumours

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2009.03.012

Two technetium-99m-labeled cholecystokinin-8 (CCK8) peptides for scintigraphic imaging of CCK receptors

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2009.03.012

The [Tc(N)(PNP)]2+ metal fragment labeled cholecystokinin-8 (CCK8) peptide for CCK-2 receptors imaging: in vitro and in vivo studies

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2009.03.012

Synthesis, chemical, radiochemical and radiobiological evaluation of a new 99mTc-labelled bombesin-like peptide

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2009.03.012

Use of radiolabeled bombesin in humans

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2009.03.012

Technetium-99m RP527, a GRP analogue for visualisation of GRP receptor-expressing malignancies: a feasibility study.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2009.03.012

Gastrin-releasing peptide receptor imaging in human breast carcinoma versus immunohistochemistry.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2009.03.012

Preparation and evaluation of 99mTc-EDDA/HYNIC-[Lys 3]-bombesin for imaging gastrin-releasing peptide receptor-positive tumours.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2009.03.012

68Ga-labeled bombesin studies in patients with gastrointestinal stromal tumors: comparison with 18F-FDG.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2009.03.012

Synthesis and evaluation of bombesin derivatives on the basis of pan-bombesin peptides labeled with indium-111, lutetium-177, and yttrium-90 for targeting bombesin receptor-expressing tumors

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2009.03.012

Novel 111In-labelled bombesin analogues for molecular imaging of prostate tumours

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2009.03.012

Design, synthesis, and biological evaluation of an antagonist-bombesin analogue as targeting vector

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2009.03.012

Evaluation of the pharmacokinetic effects of various linking group using the 111In-DOTA-X-BBN(7-14)NH2 structural paradigm in a prostate cancer model

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2009.03.012

[99mTc]Demobesin 1, a novel potent bombesin analogue for GRP receptor-targeted tumour imaging

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2009.03.012

Bombesin receptor antagonists may be preferable to agonists for tumor targeting

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2009.03.012

Potent bombesin-like peptides for GRP-receptor targeting of tumors with 99mTc: a preclinical study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2009.03.012

Pyrazolyl conjugates of bombesin: a new tridentate ligand framework for the stabilization of fac-[M(CO)3]+ moiety

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2009.03.012

Radiolabeled bombesin analogs for prostate cancer diagnosis: preclinical studies

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2009.03.012

Chemical and biological characterization of new Re(CO)3/[99mTc](CO)3 bombesin analogues

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2009.03.012

99mTc-labeled bombesin(7-14)NH2 with favorable properties for SPECT imaging of colon cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2009.03.012

99mTc(CO)3-DTMA bombesin conjugates having high affinity for the GRP receptor

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2009.03.012

DOTA-PESIN, a DOTA-conjugated bombesin derivative designed for the imaging and targeted radionuclide treatment of bombesin receptor-positive tumours

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2009.03.012

Comparative in vitro and in vivo evaluation of two 64Cu-labeled bombesin analogs in a mouse model of human prostate adenocarcinoma.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2009.03.012

In vivo evaluation and small-animal PET/CT of a prostate cancer mouse model using 64Cu bombesin analogs: side-by-side comparison of the CB-TE2A and DOTA chelation systems

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2009.03.012

[64Cu-NOTA-8-Aoc-BBN(7-14)NH2] targeting vector for positron-emission tomography imaging of gastrin-releasing peptide receptor-expressing tissues

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2009.03.012

In vitro and in vivo evaluation of 64Cu-labeled DOTA-linker-bombesin(7-14) analogues containing different amino acid linker moieties

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2009.03.012

Molecular imaging of gastrin-releasing peptide receptor-positive tumors in mice using 64Cu- and 86Y-DOTA-(Pro1,Tyr4)-bombesin(1-14).

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2009.03.012

18F-labeled BBN-RGD heterodimer for prostate cancer imaging

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2009.03.012

Synthesis, 18F-labeling, and in vitro and in vivo studies of bombesin peptides modified with silicon-based building blocks.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2009.03.012

BisMSH-DTPA. A potential imaging agent for malignant melanoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2009.03.012

Radioiodination of rhenium cyclized alpha-melanocyte-stimulating hormone resulting in enhanced radioactivity localization and retention in melanoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2009.03.012

203Pb-labeled alpha-melanocyte-stimulating hormone peptide as an imaging probe for melanoma detection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2009.03.012

111In-labeled lactam bridge-cyclized alpha-melanocyte stimulating hormone peptide analogues for melanoma imaging

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2009.03.012

A (99m)Tc(CO)(3)-labeled pyrazolyl-alpha-melanocyte-stimulating hormone analog conjugate for melanoma targeting

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2009.03.012

Gallium-68-labeled DOTA-rhenium-cyclized alpha-melanocyte-stimulating hormone analog for imaging of malignant melanoma.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2009.03.012

Imaging of melanoma using 64Cu- and 86Y-DOTA-ReCCMSH(Arg11), a cyclized peptide analogue of alpha-MSH.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2009.03.012

64Cu-labeled alpha-melanocyte-stimulating hormone analog for microPET imaging of melanocortin 1 receptor expression

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2009.03.012

Small-animal PET of melanocortin 1 receptor expression using a 18F-labeled alpha-melanocyte-stimulating hormone analog

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2009.03.012

Vasoactive intestinal peptide receptor scintigraphy in patients with pancreatic adenocarcinomas or neuroendocrine tumours

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2009.03.012

99mTc(CO)3-VIP analogues: preparation and evaluation as tumor imaging agent.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2009.03.012

PET imaging of VPAC1 expression in experimental and spontaneous prostate cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2009.03.012

Radiolabeling and in vitro and in vivo characterization of [18F]FB-[R(8,15,21), L17]-VIP as a PET imaging agent for tumor overexpressed VIP receptors.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2009.03.012

Stabilised 111In-labelled DTPA- and DOTA-conjugated neurotensin analogues for imaging and therapy of exocrine pancreatic cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2009.03.012

Radionuclide imaging of small-cell lung cancer (SCLC) using 99mTc-labeled neurotensin peptide 8-13.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2009.03.012

Toward stable N4-modified neurotensins for NTS1-receptor-targeted tumor imaging with 99mTc

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2009.03.012

[99mTc]Demotensin 5 and 6 in the NTS1-R-targeted imaging of tumours: synthesis and preclinical results.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2009.03.012

Double-stabilized neurotensin analogues as potential radiopharmaceuticals for NTR-positive tumors.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2009.03.012

Glucagon-like peptide 1-receptor scans to localize occult insulinomas.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2009.03.012

Novel chemically modified analogues of neuropeptide Y for tumor targeting

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2009.03.012

Development of a 111In-labeled peptide derivative targeting a chemokine receptor, CXCR4, for imaging tumors

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2009.03.012

Quantitation of CXCR4 expression in myocardial infarction using 99mTc-labeled SDF-1alpha

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2009.03.012

Somatostatin receptor sst1-sst5 expression in normal and neoplastic human tissues using receptor autoradiography with subtype-selective ligands

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2009.03.012

NPY receptors in human cancer: a review of current knowledge

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2009.03.012

GLP-1 receptor expression in human tumors and human normal tissues: potential for in vivo targeting.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2009.03.012

Peptide receptors as molecular targets for cancer diagnosis and therapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2009.03.012

Co-expressed peptide receptors in breast cancer as a molecular basis for in vivo multireceptor tumour targeting

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2009.03.012

Concomitant expression of several peptide receptors in neuroendocrine tumours: molecular basis for in vivo multireceptor tumour targeting

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2009.03.012

Is there a role for agonist gastrin-releasing peptide receptor radioligands in tumour imaging?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2009.03.012

The CXCR4 chemokine receptor in acute and chronic leukaemia: a marrow homing receptor and potential therapeutic target

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2009.03.012

Somatostatin receptor subtype 2-mediated uptake of radiolabelled somatostatin analogues in the human kidney

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2009.03.012

MicroPET imaging of a gastrin-releasing peptide receptor-positive tumor in a mouse model of human prostate cancer using a 64Cu-labeled bombesin analogue.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2009.03.012

The somatostatin receptor-targeted radiotherapeutic [90Y-DOTA-DPhe1, Tyr3]octreotide (90Y-SMT 487) eradicates experimental rat pancreatic CA 20948 tumours.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2009.03.012

Characterisation of gastrin receptors on a rat pancreatic acinar cell line (AR42J). A possible model for studying gastrin mediated cell growth and proliferation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2009.03.012

Characterization of high-affinity receptors for bombesin/gastrin releasing peptide on the human prostate cancer cell lines PC-3 and DU-145: internalization of receptor bound 125I-(Tyr4) bombesin by tumor cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2009.03.012

Comparison of an 18F Labeled Derivative of Vasoactive Intestinal Peptide and 2-Deoxy-2-[18F]Fluoro-D-Glucose in Nude Mice Bearing Breast Cancer Xenografts

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2009.03.012

Activation of phosphatidylinositol turnover by neurotensin receptors in the human colonic adenocarcinoma cell line HT29.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2009.03.012

Solubilization of active GLP‐1 (7–36)amide receptors from RINm5F plasma membranes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2009.03.012

Differently labeled peptide ligands for rapid investigation of receptor expression on a new human glioblastoma cell line

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2009.03.012

Expression of receptors for luteinizing hormone-releasing hormone in human ovarian and endometrial cancers: frequency, autoregulation, and correlation with direct antiproliferative activity of luteinizing hormone-releasing hormone analogues

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2009.03.012

Development of novel 68Ga- and 18F-labeled GnRH-I analogues with high GnRHR-targeting efficiency

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2009.03.012

The somatostatin receptor family.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2009.03.012

Receptor-specific somatostatin analogs: correlations with biological activity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2009.03.012

A transplantable human carcinoid as model for somatostatin receptor-mediated and amine transporter-mediated radionuclide uptake

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2009.03.012

Somatostatin receptor gene expression in neuroblastoma.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2009.03.012

Characterization of somatostatin receptor subtype 2 expression in stably transfected A-427 human cancer cells.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2009.03.012

Tissue distribution of octreotide binding receptors in normal mice and strains prone to autoimmunity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2009.03.012

Renal uptake and retention of radiolabeled somatostatin, bombesin, neurotensin, minigastrin and CCK analogues: species and gender differences.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2009.03.012

A new radiolabelled somatostatin analogue [111In-DTPA-D-Phe1]RC-160: preparation, biological activity, receptor scintigraphy in rats and comparison with [111In-DTPA-D-Phe1]octreotide

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2009.03.012

Use of the incretin hormone glucagon-like peptide-1 (GLP-1) for the detection of insulinomas: initial experimental results

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2009.03.012

Somatostatin and somatostatin analogues: pharmacokinetics and pharmacodynamic effects

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2009.03.012

[18F]Galacto-RGD: synthesis, radiolabeling, metabolic stability, and radiation dose estimates

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2009.03.012

N-terminal sugar conjugation and C-terminal Thr-for-Thr(ol) exchange in radioiodinated Tyr3-octreotide: effect on cellular ligand trafficking in vitro and tumor accumulation in vivo

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2009.03.012

Design and in vitro characterization of highly sst2-selective somatostatin antagonists suitable for radiotargeting

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2009.03.012

A new peptidic somatostatin agonist with high affinity to all five somatostatin receptors

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2009.03.012

NODAGATOC, a new chelator-coupled somatostatin analogue labeled with [67/68Ga] and [111In] for SPECT, PET, and targeted therapeutic applications of somatostatin receptor (hsst2) expressing tumors

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2009.03.012

NODAPA-OH and NODAPA-(NCS)n: synthesis, 68Ga-radiolabelling and in vitro characterisation of novel versatile bifunctional chelators for molecular imaging

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2009.03.012

In vivo transchelation of copper-64 from TETA-octreotide to superoxide dismutase in rat liver.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2009.03.012

Linker effects on biological properties of 111In-labeled DTPA conjugates of a cyclic RGDfK dimer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2009.03.012

Noninvasive visualization of the activated alphavbeta3 integrin in cancer patients by positron emission tomography and [18F]Galacto-RGD

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2009.03.012

Tumour uptake of the radiolabelled somatostatin analogue [DOTA0, TYR3]octreotide is dependent on the peptide amount

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2009.03.012

Somatostatin receptor-mediated imaging and therapy: basic science, current knowledge, limitations and future perspectives

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2009.03.012

The importance of high specific radioactivity in the performance of 68Ga-labeled peptide

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2009.03.012

Renal metabolism of 111In-DTPA-D-Phe1-octreotide in vivo

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2009.03.012

Between the Scylla and Charybdis of peptide radionuclide therapy: hitting the tumor and saving the kidney

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2009.03.012

Localisation and mechanism of renal retention of radiolabelled somatostatin analogues

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2009.03.012

Effect of molecular charges on renal uptake of 111In-DTPA-conjugated peptides

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2009.03.012

Effect of carboxyl-group of D-glutamic acid or gamma-carboxy-D-glutamic acid as N-terminal amino acid of (111)in-diethylenetriaminepentaacetic acid-octreotide on accumulation of radioactivity in kidney

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2009.03.012

Renal uptake and metabolism of radiopharmaceuticals derived from peptides and proteins

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2009.03.012

Amino acid infusion blocks renal tubular uptake of an indium-labelled somatostatin analogue

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2009.03.012

Safe and effective inhibition of renal uptake of radiolabelled octreotide by a combination of lysine and arginine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2009.03.012

Indication for different mechanisms of kidney uptake of radiolabeled peptides.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2009.03.012

Reducing renal uptake of radiolabeled peptides using albumin fragments

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2009.03.012

Endocytosis of the somatostatin analogue, octreotide, by the proximal tubule-derived opossum kidney (OK) cell line.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2009.03.012

Molecular imaging of reduced renal uptake of radiolabelled [DOTA0,Tyr3]octreotate by the combination of lysine and Gelofusine in rats.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2009.03.012

Imaging tumors in humans with Tc-99m-VIP.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2009.03.012

10.1016/J.YMETH.2009.03.012

7 January 2021

Identifiers

DOI

1 reference

20 August 2017

1 reference

PubMed ID

19324088